作者: Kenichi Suda , Christopher J Rivard , Tetsuya Mitsudomi , Fred R Hirsch
DOI: 10.1080/14737140.2017.1355243
关键词:
摘要: ABSTRACTIntroduction: despite initial dramatic efficacy of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancer patients, emergence acquired resistance is almost inevitable. The T790M secondary mutation that accounts for ~50% now treatable with osimertinib. However, the remaining 50% patients who develop mechanisms other than mutation, cytotoxic chemotherapies are still standard care and novel treatment strategies urgently needed.Areas covered: In this review, we discuss current experimental clinical evidence to better overcome or prevent EGFR-TKIs cancers, focusing on non-T790M mechanisms.Expert commentary: There numerous resistant EGFR-TKIs, therefore, can be applied many these may reasonable useful practice. Although combination chemotherapy plus an EGFR-...